National Association of Medical Examiners position paper: Recommendations for the investigation and certification of deaths in people with epilepsy

Owen Middleton\textsuperscript{1} | Daniel Atherton\textsuperscript{2} | Elizabeth Bundock\textsuperscript{3} | Elizabeth Donner\textsuperscript{4} | Daniel Friedman\textsuperscript{5} | Dale Hesdorffer\textsuperscript{6} | Heather Jarrell\textsuperscript{7} | Aileen McCrillis\textsuperscript{8} | Othon J. Mena\textsuperscript{9} | Mitchel Morey\textsuperscript{1} | David Thurman\textsuperscript{10} | Niu Tian\textsuperscript{11} | Torbjörn Tomson\textsuperscript{12,13} | Zian Tseng\textsuperscript{14} | Steven White\textsuperscript{15} | Cyndi Wright\textsuperscript{16} | Orrin Devinsky\textsuperscript{5}

\textsuperscript{1}Hennepin County Medical Examiner’s Office, Minneapolis, MN, USA
\textsuperscript{2}Anatomic Pathology, Division of Forensic Pathology, Cooper Green Hospital, University of Alabama at Birmingham, Birmingham, AL, USA
\textsuperscript{3}Office of the Chief Medical Examiner, Burlington, VT, USA
\textsuperscript{4}Comprehensive Epilepsy Program, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada
\textsuperscript{5}Department of Neurology, Langone Comprehensive Epilepsy Center, New York University, New York, NY, USA
\textsuperscript{6}Gertrude H Sergievsky Center and Department of Epidemiology, Columbia University, New York, NY, USA
\textsuperscript{7}Office of the Medical Investigator, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
\textsuperscript{8}New York University Langone Health, New York University School of Medicine, New York, NY, USA
\textsuperscript{9}Ventura County Office of Chief Medical Examiner, Ventura, CA, USA
\textsuperscript{10}Department of Neurology, School of Medicine, Emory University, Atlanta, GA, USA
\textsuperscript{11}Division of Population Health, Epilepsy Program, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA, USA
\textsuperscript{12}Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
\textsuperscript{13}Department of Neurology, Karolinska University Hospital, Stockholm, Sweden
\textsuperscript{14}Cardiac Electrophysiology Section, Cardiology Division, University of California, San Francisco, San Francisco, CA, USA
\textsuperscript{15}Office of the Medical Examiner, Cook County, Chicago, IL, USA
\textsuperscript{16}Stormlab Consulting, Burlingame, CA, USA

Correspondence
Owen Middleton, Hennepin County Medical Examiner’s Office, Minneapolis, MN, USA.
Email: owen.middleton@hennepin.us

Summary
Sudden unexpected death of an individual with epilepsy can pose a challenge to death investigators, as most deaths are unobserved, and the individual is commonly found dead in bed. Anatomic findings (e.g., tongue/lip bite) are commonly absent and of varying specificity, thereby limiting the evidence to implicate epilepsy as a cause of or contributor to death. Thus it is likely that death certificates significantly underrepresent the true number of deaths in which epilepsy was a factor. To address this, members of the National Association of Medical Examiners, North American SUDEP Registry, Epilepsy Foundation SUDEP Institute, American Epilepsy Society, and the Centers for Disease Control and Prevention constituted an expert panel to generate evidence-based recommendations for the investigation and certification of deaths in people with epilepsy.
practice of death investigation and autopsy, toxicological analysis, interpretation of autopsy and toxicology findings, and death certification to improve the precision of death certificate data available for public health surveillance of epilepsy-related deaths. The recommendations provided in this paper are intended to assist medical examiners, coroners, and death investigators when a sudden unexpected death in a person with epilepsy is encountered.

**KEYWORDS**

autopsy, death investigation, epilepsy, mortality, sudden unexpected death in epilepsy

## 1 | INTRODUCTION

The investigation and certification of deaths in patients with seizures and epilepsy vary within and between medical examiners’ and coroners’ offices.¹,² This variation, together with varied terms and criteria to diagnose and classify seizures and epilepsies, and possible comorbid disease (e.g., cardiovascular), challenges the determination of cause of death (COD) in seizure- and epilepsy-related death, and likely underestimates the frequency of these deaths.

To help address these limitations, the National Association of Medical Examiners, North American SUDEP Registry, Epilepsy Foundation SUDEP Institute, American Epilepsy Society, and the Centers for Disease Control and Prevention (CDC), constituted an expert panel (pathologists/medical examiners [7], epileptologists [6], epidemiologists [3], cardiologist [1], and a health sciences librarian [1]) to establish recommendations for death investigation and certification of epilepsy-related deaths. The peer-reviewed literature was examined for deaths among individuals with seizures and epilepsy. The goal was to better inform the public health burden of seizures and epilepsy-related death and improve surveillance by developing evidence-based recommendations for the practice and interpretation of death investigation, autopsy, toxicological analysis, and death certification. The panel formulated 7 questions to address best practices for effective identification of seizure- and epilepsy-related death (Table 1). These questions were arranged in the order that typically arises during death investigation. The recommendations were reviewed by each society for comments and eventual endorsement. Respective organizations at CDC also provided review and comment.

## 2 | BACKGROUND

A seizure is a sudden behavioral change resulting from excessive synchronous electrical activity in the brain. Seizures may be provoked (also known as acute symptomatic; e.g., fever in a young child, drug intoxication or withdrawal, electrolyte imbalance) or unprovoked, resulting from a genetic, developmental, acquired (e.g., trauma, tumor, stroke), or unknown cause. Epilepsy is diagnosed when a person has 2 or more unprovoked seizures or has a single unprovoked seizure with an enduring tendency for additional seizures.³ “Seizure disorders” are aggregated with “seizures” in the National Vital Statistics System. However, seizure disorder can refer to individuals without epilepsy (e.g., 2 provoked seizures). Because of these potential confounds, we recommend the term epilepsy over seizure disorder when clinically defined.

Epilepsy affects 3.4 million Americans.⁴ Individuals with epilepsy have up to 11-fold higher mortality rates compared to matched controls.² Natural causes of death are increased 15-fold. Nonnatural causes are also increased (falls—8-fold; drowning—7.7-fold; drug poisoning—5.1-fold; suicide 3.5 to 5-fold).⁵ Psychiatric disorders occur in 75% of those with nonnatural causes. Among United States young adults with epilepsy and low socioeconomic status, deaths occur 17 years prematurely.⁶

The incidence of sudden death among young adults with epilepsy is 24- to 27-fold higher than in control populations.⁷,⁸ Sudden unexpected death in epilepsy (SUDEP) is a sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning death, occurring in benign circumstances, in an individual with epilepsy, with or without evidence for a seizure and excluding documented status epilepticus, in which postmortem examination does not
TABLE 1 Questions formulated by the panel to address seizure- and epilepsy-related deaths

<table>
<thead>
<tr>
<th>Question</th>
<th>Question text</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Within the bounds of state law, which deaths require assumption of jurisdiction and performance of an autopsy?</td>
</tr>
<tr>
<td>2</td>
<td>What constitutes appropriate and necessary scene investigation, epilepsy screening, and follow-up?</td>
</tr>
<tr>
<td>3</td>
<td>When is it appropriate or necessary to perform toxicology and/or antiepileptic seizure medication testing?</td>
</tr>
<tr>
<td>4</td>
<td>What are the best samples to collect for laboratory testing and histologic analysis?</td>
</tr>
<tr>
<td>5</td>
<td>How are scene findings, autopsy findings, toxicology, and histology interpreted?</td>
</tr>
<tr>
<td>6</td>
<td>How are competing causes of sudden death assessed?</td>
</tr>
<tr>
<td>7</td>
<td>What are the optimal methods for determining and certifying cause of death, manner of death, and how injury occurred?</td>
</tr>
</tbody>
</table>

reveal a cause of death (Definite SUDEP), without post-mortem examination but without other potential cause of death (Probable SUDEP), or with a competing cause of death (Possible SUDEP). The strongest risk factor for SUDEP is poor control of primary or secondary generalized tonic–clonic seizures (GTCS). Structural brain lesions, focal abnormalities on neurological examination, intellectual disability, alcohol abuse, and anxiolytic use are associated with increased SUDEP risk in some studies.

A potential confound in SUDEP is sudden cardiac death (SCD). Among “SCDs” in epilepsy patients, 70% are unwitnessed; 34% of witnessed cases had seizure activity before “SCD.” Because 90% of SUDEPs are unwitnessed, a most people with epilepsy whose deaths were classified as “SCD” may have died from epilepsy. Misclassification of an epilepsy-related death as SCD is supported by higher rates of bradyarrhythmias and asystole (typical of epilepsy) and lower rates of ventricular arrhythmias in epilepsy patients with “SCD” than in nonepilepsy patients. In addition, moderate coronary artery disease can suggest a primary cardiac cause of death in a person with epilepsy (PWE) but cannot exclude an epilepsy-related death.

3  METHODS

We conducted electronic literature searches using the databases Medline (Ovid), Medline In-Process & other Non-indexed Citations (Ovid), Embase (Ovid), and PubMed.gov for articles published in English from 1970 to January 2016. Databases were searched using both subject headings and text keywords that describe epilepsy-related mortality and death investigation (the complete search strategy is in the Appendix). Academic Forensic Pathology was also searched with keywords related to epilepsy and seizure.

Pairs of authors reviewed all the references yielded from the literature search using a 2-step process. First, the authors reviewed the titles and abstracts of the articles yielded from the search and excluded all irrelevant articles. The full text of the remaining articles was then reviewed for potential inclusion based on relevance to at least one of the questions and the evidence quality.

4  RESULTS/DISCUSSION

4.1 Question 1: Within the bounds of state law, which deaths in people with epilepsy require assumption of jurisdiction, and performance of an autopsy?

Medical examiners and coroners (ME/C) have the expertise and responsibility to determine the cause and manner of death in cases of sudden unexpected death. These circumstances are commonly encountered in the deaths of epilepsy patients, leading to ME/C involvement in most of these death certifications. ME/C authority to assume jurisdiction or responsibility for these determinations is typically mandated by their respective state statutes. Beyond statute, the ME/C exercises their professional judgement on jurisdiction, taking into account the circumstances of the death and resources available in their jurisdiction.

The process of assuming jurisdiction begins when a death is reported to the local ME/C, which requires awareness by reporting agencies and medical personnel of established criteria of reportable deaths. This initial connection is critical to identify epilepsy-related deaths; ME/C staff must consider the potential role of epilepsy in such instances. Once jurisdiction is assumed, an investigation ensues to acquire the information necessary for cause and manner of death determinations, which in turn, are documented in the death certificate. In a retrospective study of SUDEP death certification in Britain, inconsistencies were identified in the depth of investigations. Causes of deaths varied, “with epilepsy stated as the primary cause of death in less than half the sample.”

Autopsy may provide otherwise unavailable information necessary for death certification. The importance of complete autopsy is highlighted by a multidisciplinary team study of 335 consecutive presumed sudden cardiac deaths over a 2-year period. This study, which included complete autopsy and investigative data, concluded that 18 cases (5.4%) were actually neurologic deaths, including 6 SUDEP. A national survey was done to assess the depth and frequency of forensic autopsies in SUDEP. Generally, the autopsies were done in a consistent manner, but the
surveys identified a trend of nonurban offices performing fewer autopsies.\textsuperscript{15} If the circumstances surrounding a seizure death clearly indicate a natural event, jurisdiction may be declined by the ME/C, and an autopsy is not performed unless the family consents to a hospital autopsy or private autopsy. However, because this population tends to be younger and their deaths are frequently unwitnessed, autopsy is often required due to absence of an obvious natural cause.

Epilepsy death investigation is strongly dependent on history and scene findings, yet an autopsy is essential in excluding other causes of death, documenting comorbidities, obtaining toxicologic and histology samples, and providing neuropathologic correlation.

### 4.2 Question 2: What constitutes appropriate and necessary scene investigation, epilepsy screening, and follow-up?

The panel supports the practices recommended in the United States Department of Justice (USDOJ) National Institute of Justice (NIJ) Death Investigation Guidelines published by the USDOJ.\textsuperscript{16} When death occurs outside the hospital, the environment and position of the body should be detailed to help objectively interpret the circumstances. For example, understanding whether a PWE was found submerged in a bathtub full of water or prone on a bed with the external airways occluded by bedding material is crucial for eventual death certification. Knowing whether a death was witnessed or unwitnessed is also important. If witnessed, investigators should ask if the decedent had a seizure before becoming unresponsive and attempt to describe the initial behavioral changes or seizure movements. Documentation should include observations supportive of a tonic–clonic seizure event, such as disheveled bedding; biting of the tongue, lip, or cheek; or saliva/foam around the mouth. Medications and medication containers at the scene should be inventoried, especially antiepileptic drugs.

Investigators should ask family or other witnesses at the scene about the decedent’s medical history, striving for as specific of an epilepsy diagnosis as possible. At a minimum, the investigator should try to determine whether a decedent had convulsive or nonconvulsive seizures because this history may only be obtained with specific questions, and convulsive seizures significantly increase the risk of SUDEP (an example of questions to assist death investigators in gathering such information is provided in the Appendix). Primary care providers and neurologists should be contacted in follow-up, when known. If emergency medical personnel responded to the scene, those records should be reviewed, and a copy of available electrocardiograph tracings/interpretations should be sought.

### 4.3 Question 3: When is it appropriate or necessary to perform toxicology and/or antiepileptic seizure medication testing?

In the absence of a specific anatomic cause of death following autopsy, when specimens are available, toxicology testing, including antiepileptic drug concentrations, should be performed. Results may reveal drug toxicity from illicit or prescribed substances as a potential cause of death. Documentation of postmortem antiepileptic drug concentrations can aid the investigation when death is potentially epilepsy-related. If the decedent was admitted to an emergency department or hospital before death, postmortem testing should be performed on the earliest blood specimen.

### 4.4 Question 4: What are the best samples to collect for laboratory testing and histologic analysis?

Blood, tissue, and other fluid samples should be retained as per the jurisdiction’s usual protocol for routine toxicology testing. Special consideration should be given for potential genetic studies, given the more than 100 genetic disorders associated with epilepsy, with new genes identified each year. Genetic channelopathies, most often sodium and potassium channel gene mutations, may contribute to SUDEP, since these genes are expressed in the brain and heart, and may lower seizure threshold and cause cardiac arrhythmias.\textsuperscript{17,18} Given the possible implications for surviving relatives, collection of proper samples is essential. An ethylenediaminetetraacetic acid (EDTA—purple top) tube of blood is the preferred specimen for genetic testing, but a blood spot card or frozen tissue (1 cubic centimeter of liver, spleen, or heart at −80°C) can also be used.\textsuperscript{19}

Extended brain examination is recommended in potential epilepsy-related death cases, following brain fixation in formalin solution for a minimum of 2 weeks. Although examination by a neuropathologist is preferred, limitation of resources, objection to organ retention, or other factors will necessitate the autopsy pathologist’s discretion for such consultation. Previously published recommendations for microscopic analysis of the brain are outlined in Table 2. Patients with epilepsy may have cardiac pathology resulting from seizures as well as comorbid disorders (eg, hypertension, hyperlipidemia), with findings of irreversible changes characterized by myocyte hypertrophy and perivascular and interstitial fibrosis, and reversible change characterized by subendocardial myocyte vacuolization.\textsuperscript{20} Others have recommended inclusion of 3 left ventricle and 1 right ventricle heart sections, lung, and any grossly abnormal organs for histologic examination, but individual practice varies.\textsuperscript{21}
4.5 | Question 5: How are scene findings, autopsy findings, toxicology, and histology interpreted?

In epilepsy-related deaths, the purposes of the scene investigation, autopsy, and ancillary tests are the following: (1) to determine that epilepsy has/not contributed to the death; (2) to identify the underlying etiology of epilepsy, if present; and (3) to assess comorbidities. Autopsy and ancillary test findings must be interpreted in the context of a thorough death investigation to accurately determine the cause and manner of death. The utility and limitations of several anatomic findings frequently encountered in epilepsy-related deaths are discussed.

4.5.1 | Livor pattern/body position

The distribution of livor mortis may help in the context of positional asphyxia or smothering, by revealing pressure marks from objects against the chest, neck, nose, or mouth that may have restricted breathing. The extent to which such external factors contribute to death vary from case to case. Prone position is associated with SUDEP. The significance of finding the decedent’s face (nose/mouth) against a surface (often bedding) must be interpreted in the totality of autopsy and scene findings. Such a position is potentially threatening when the brain’s reflexive response to the environmental challenge is impaired, for example, during intoxication or after/after seizure. Without the seizure or postictal state, the environmental challenge would have been nonlethal. In some cases, livor pattern and scene reconstruction reveal evidence of an asphyxial component by compression of the chest or neck, with or without petechiae. Although historically considered an indicator of asphyxia and found in some SUDEPs, petechiae occur in deaths resulting from diverse mechanisms and causes and therefore do not establish terminal asphyxia without corroborating findings and circumstances.

4.5.2 | Tongue, lip, or inner cheek trauma

Contusion or laceration of the tongue, lip, or inner cheek supports, but is not diagnostic of, a seizure. Tongue trauma occurs in 17%-50% of seizure-related deaths. Tongue trauma in other causes of death is uncommon; 1 study found tongue/lip contusions in 37% of SUDEP cases but no controls. It is worth removing the tongue for examination. Trauma to the sides of the tongue or involving the buccal mucosa may be more helpful, since small contusions of the tongue tip may occur during intubation/attempted intubation.

4.5.3 | Intinence of urine

Although a helpful sign in evaluating living patients with epilepsy, urinary incontinence is so ubiquitous at death scenes that it cannot establish the occurrence of a terminal seizure.

4.5.4 | Gastric contents in airway

Gastric contents are frequently found in the airways at autopsy, having been displaced there during compressions of the chest for resuscitation, during manipulation of the body after death, or by increased abdominal pressure during decomposition. The presence of gastric contents in the trachea and proximal bronchi should not be interpreted as mechanistically significant to the cause of death or as evidence of seizure activity and therefore does not exclude SUDEP. Abundant gastric contents in distal airways is more concerning for true aspiration if there was no mechanical ventilation or chest compressions. Occlusion of the upper airway by food is a significant finding and a choking event must be considered; such a death is not SUDEP but is epilepsy-related if the individual was eating when a seizure occurred.

4.5.5 | Pulmonary edema

Pulmonary edema is a nonspecific finding, commonly found at autopsy in deaths of various neurogenic or cardio- genic causes, including SUDEP. In animal models, neuro- genic pulmonary edema in seizure deaths may result from a sympathetic surge with increased hydrostatic pressure in the left atrium, pulmonary artery, and pulmonary microvas- culature, leading to a capillary-alveolar membrane with increased permeability. Autopsy series of SUDEP show that pulmonary edema and congestion occur in 62%-100% of cases, but fail to demonstrate a statistically significant increase between SUDEP and controls. The absence of pulmonary edema does not exclude an epilepsy-related death.
of brains examined in the fresh state. \[52x407\]

Histologic examination can exclude competing (non–epilepsy-related) causes, not to the lack of an anatomic etiology for the epilepsy. Persons with epilepsy of any etiology may die suddenly and unexpectedly.

Seizure and epilepsy can result from diverse brain pathologies such as trauma, tumor, vascular malformation, cerebral infarct, abscess, parasitic cysts, Rasmussen encephalitis, other chronic encephalitides, and malformations of cortical development. Mesial temporal sclerosis refers to chronic changes in the hippocampus (hippocampal sclerosis), amygdala, and entorhinal cortex that are closely associated with temporal lobe epilepsy. Mesial temporal sclerosis/hippocampal sclerosis may be a complication or cause of epilepsy and does not need to be on the death certificate. The diverse neuropathologic findings in patients with epilepsy have been reviewed, and are beyond the scope of this article. When a neuropathologic lesion or disease is a probable cause of epilepsy, it should be listed as the underlying etiology. Traumatic brain injury may be an etiology for epilepsy, a consequence of epilepsy, or both, and one must seek historical data to determine whether the traumatic lesions predate the onset of epilepsy (eg, post-traumatic epilepsy) or whether the brain injury occurred during a seizure of unknown or other cause. Because late sequelae of traumatic brain injury are a common etiology for epilepsy, not all SUDEP cases will have a natural manner of death.

### 4.5.7 Neuropathologic findings

Neuropathologic examination can exclude competing causes of death, identify potentially epileptogenic lesions, and determine whether repeated seizures have caused brain injury (eg, hippocampal sclerosis or cerebellar atrophy). The brain should be examined after formalin fixation in cases of SUDEP and epilepsy-related deaths occurring within 24 hours of last seizure. Histologic examination should be performed even when no macroscopic pathology is identified. However, absence of neuronal injury or identifiable pathology is consistent with the clinical diagnosis of epilepsy.

A common misconception is that the brain is normal anatomically in most SUDEP cases. Neuropathologic abnormalities in autopsy series of SUDEP and epilepsy-related deaths occur in 46%–71%. The SUDEP criterion that no anatomic cause of death be identified refers to competing (non–epilepsy-related) causes, not to the lack of an anatomic etiology for the epilepsy. Persons with epilepsy of any etiology may die suddenly and unexpectedly.

Seizure and epilepsy can result from diverse brain pathologies such as trauma, tumor, vascular malformation, cerebral infarct, abscess, parasitic cysts, Rasmussen encephalitis, other chronic encephalitides, and malformations of cortical development. Mesial temporal sclerosis refers to chronic changes in the hippocampus (hippocampal sclerosis), amygdala, and entorhinal cortex that are closely associated with temporal lobe epilepsy. Mesial temporal sclerosis/hippocampal sclerosis may be a complication or cause of epilepsy and does not need to be on the death certificate. The diverse neuropathologic findings in patients with epilepsy have been reviewed, and are beyond the scope of this article. When a neuropathologic lesion or disease is a probable cause of epilepsy, it should be listed as the underlying etiology. Traumatic brain injury may be an etiology for epilepsy, a consequence of epilepsy, or both, and one must seek historical data to determine whether the traumatic lesions predate the onset of epilepsy (eg, post-traumatic epilepsy) or whether the brain injury occurred during a seizure of unknown or other cause. Because late sequelae of traumatic brain injury are a common etiology for epilepsy, not all SUDEP cases will have a natural manner of death.

### 4.5.8 Alcohol and drugs of abuse

The co-occurrence of epilepsy, acute symptomatic seizures, and substance abuse is common, with at least one-third of seizure-related deaths having a history of alcohol and/or street drug use. Among 83 deaths in persons with epilepsy/seizure history and no macroscopically obvious cause of death at autopsy, 21% of deaths were attributed to alcohol and or drugs. Death due to acute intoxication or withdrawal precludes classification as SUDEP, but should not prohibit inclusion of epilepsy as a contributor to death. Patients whose seizures occur exclusively in association with alcohol intoxication or withdrawal (provoked or acute symptomatic seizure) do not meet diagnostic criteria for epilepsy. However, alcohol use is a seizure trigger in people with epilepsy. Such seizures typically occur within 48 hours after peak blood levels, when the brain rebounds into a hyperexcitable state. Therefore, alcohol intoxication/withdrawal may contribute to the sudden death of a PWE, similar to other provocative factors such as missed medication or sleep deprivation. Complicating the dichotomy of epilepsy versus acute symptomatic seizures, alcohol abuse is an independent risk factor for epilepsy and may result from traumatic brain injury during intoxication, neurotoxic effects of alcohol, or kindling of epilepsy following repetitive bouts of alcohol withdrawal. Therefore, determining whether recurrent seizures in individuals with alcohol abuse are due to alcohol withdrawal or spontaneous, unprovoked seizures (epilepsy) can be very difficult. One study of first seizure in individuals with alcohol abuse found no consistent temporal relationship of seizure to last drink, suggesting that alcohol use and terminal seizure may be incidental in some decedents.

Cocaine or methamphetamine intoxication can trigger seizure activity in persons with or without epilepsy and is certified as an accidental drug death. However, if a person with documented epilepsy dies several hours after cocaine use and cocaine levels are low, then epilepsy may be a contributory cause of death. Many patients with epilepsy use cannabinoid oils and marijuana. The relevance of these substances to sudden death is unknown. However, synthetic cannabinoids (eg, spice, K2, bath salts) are pro-convulsant, and intoxication can cause seizures in
individuals without epilepsy.\textsuperscript{44} Other drugs of abuse can provoke seizures, such as 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Molly), phencyclidine (PCP), and some opiates, typically in severe intoxication.\textsuperscript{45}

4.5.9 | Antiepileptic drugs (AEDs)

AEDs at effective doses may be associated with a reduced incidence of SUDEP.\textsuperscript{46} Subtherapeutic or absent AED levels are found in 57%-92% of SUDEP cases.\textsuperscript{27,30,35,47–49} However, finding subtherapeutic AED levels at autopsy has limited value in determining cause of death due to uncertainties in the correlation of postmortem whole blood levels to antemortem serum levels and the definition of a therapeutic level. Postmortem AED levels may not be comparable to antemortem levels. Among 16 institutionalized adults with epilepsy, paired antemortem and postmortem serum samples revealed that phenobarbital, phenytoin, and carbamazepine were significantly lower in postmortem than antemortem samples.\textsuperscript{50} An animal study found that phenytoin levels were higher antemortem, whereas carbamazepine levels were similar in antemortem and postmortem samples.\textsuperscript{51} Postmortem alterations rather than patient noncompliance may explain the high incidence of subtherapeutic AED levels in SUDEP. Supporting this, there were no significant differences between postmortem AED levels between 44 SUDEP cases and 44 persons with epilepsy who died from non–epilepsy-related causes.\textsuperscript{52} The definition of a “therapeutic” range is limited because individual patients require different levels for efficacy. AED levels are informative postmortem when below detectable limits or in the lethal range.

Some AEDs can prolong the QT interval, but do not increase the risk of arrhythmia for most patients.\textsuperscript{53} When additional risk factors for arrhythmia are present, such as underlying cardiac dysfunction, electrolyte imbalance (eg, hypokalemia or hypomagnesemia), or concurrent use of other medications that prolong the QT interval, an additive effect from the AED may be considered, but it is not definitive. Fatal adverse drug reactions to AEDs (eg, hepatic failure, bone marrow suppression, Stevens-Johnson syndrome, disseminated intravascular coagulation, and pancreatitis) should be considered, but such deaths would not be classified as SUDEP. In the setting of very high, toxic levels of AEDs, suicide may be a consideration.

4.6 | Questions 6: How are competing causes of sudden death assessed?

A PWE may have a medical history, or at postmortem examination may have natural disease findings, which can explain the sudden death. The most common is atherosclerotic cardiovascular disease\textsuperscript{54}; others include cardiomegaly\textsuperscript{33} and myocarditis.\textsuperscript{55} Epilepsy is associated with such findings in some studies,\textsuperscript{20,56,57} and seizures can affect the cardiovascular system.\textsuperscript{58,59} Cardiac arrhythmia may be an undetectable cause of some SUDEPs.\textsuperscript{60} Although cardiovascular disease is the most frequent competing cause of death, the following recommendations apply to other findings associated with sudden death such as liver or pulmonary disease.

4.6.1 | Coronary artery disease

Coronary atherosclerosis is highly prevalent in the developed world and is a common postmortem finding, which may or may not contribute to or cause sudden death in a PWE. In up to half of cases, sudden death is the initial manifestation of coronary artery disease.\textsuperscript{61} Characteristics of the plaque and vessel, degree of luminal stenosis, and location\textsuperscript{62,63} should be considered when weighing coronary disease as a competing cause of sudden death. These frequent pathological findings in a PWE may represent concurrent cardiac disease that is incidental to or explains the sudden death. Close examination of gross and microscopic findings, rather than just an estimate of the percent of coronary stenosis may facilitate deciphering these 2 competing causes of death. In a PWE, finding severe coronary stenosis, coronary thrombus, cardiomegaly, large ventricular chambers, and/or acute myocardial infarction or ischemia in territories served by stenotic coronary arteries may support cardiac disease rather than epilepsy as the cause of sudden death.

In a PWE with terminal seizure and postmortem acute coronary findings, the elevated stress and sympathetic response to the seizure may have triggered the acute coronary event. Seizures can also cause fatal arrhythmias\textsuperscript{14,60} or pulmonary dysfunction.\textsuperscript{64–66} Thus even when a PWE has acute cardiac findings it is possible that a seizure triggered the cardiac ischemic event or arrhythmia, especially in the setting of preexisting cardiac disease, or vice versa. This scenario should be considered when there is evidence of seizure (eg, witnessed or tongue bite) and acute cardiac changes.

4.6.2 | Structural cardiomyopathies and primary electrical causes of sudden cardiac death

Other cardiac causes of sudden death include structural cardiac diseases such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy, and valvular disease (eg, critical aortic stenosis); these causes are apparent on postmortem examination in a PWE. Nonstructural or “autopsy negative” molecular cardiac (primary electrical) diseases affecting cardiac channels and causing sudden arrhythmic death (eg,
congenital long-QT or Brugada syndromes, catecholaminergic polymorphic ventricular tachycardia (CPVT)) are uncommon but potential causes of sudden death in a PWE. As with the general population, a cardiac etiology for sudden death cannot be entirely excluded with postmortem findings of a normal heart in a PWE.

4.6.3 | Cardiac syncope mimicking seizure

Epilepsy is not the only cause for seizures. Some patients initially diagnosed with epilepsy are later found to have seizures due to a cardiovascular cause such as an arrhythmia. Rhythmic movements mistaken for generalized seizure can result from cerebral hypoperfusion during cardiac events such as ventricular tachycardia (VT), ventricular fibrillation (VF), idioventricular rhythms, or pulseless electrical activity. Detailed description of the duration (cardiac syncopal movements often <20 seconds; tonic–clonic seizures often >45 seconds) and type of movements witnessed (classic tonic phase [5-10 seconds] followed by clonic movements that progressively become less frequent over 30-180 seconds suggest a tonic–clonic seizure) may help determine seizure versus cardiac cause, but witness reports can be unreliable.

4.6.4 | Supportive data: medical history, circumstances, and cardiac rhythms

Data such as medical history, family history, witness account of terminal seizure event, and paramedic run-sheets with description of the fatal event and presenting rhythm, can help distinguish between epilepsy and a cardiac cause. A history of symptomatic cardiac disease or uncontrolled seizures while on multiple AEDs may support 1 diagnosis over another. Structural cardiomyopathies such as HCM and many primary electrical diseases have genetic causes, often with autosomal dominant inheritance patterns. Therefore, a family history of sudden cardiac death, particularly in persons younger than age 45 years, or sudden infant deaths, suggests the possibility of a genetic cause of sudden death in a PWE.

Circumstances and details surrounding the fatal seizure event can also be helpful. Sudden deaths due to cardiac primary electrical diseases (eg, long QT Syndrome [LQT1] or CPVT) occur during or just following peak exercise. Therefore, a report of seizure activity following collapse after vigorous exercise would favor a cardiac cause, whereas seizure activity at rest or in bed would favor epilepsy.

A rhythm recorded by paramedics during attempted resuscitation can also be helpful. The most common rhythms found during SUIDEP are bradyarrhythmias, whereas VT or VF are commonly found in sudden cardiac death. Although VF is often considered the sine qua non of cardiac/arrhythmic death, acute neurologic events can also cause neurocardiogenic VF; therefore, VF at the time of fatal event does not exclude a neurologic cause.

4.7 | Question 7: What are the optimal methods for determining and certifying cause of death, manner of death, and how injury occurred?

Death certificates are useful for families of the deceased, public health agencies, and researchers. Sections of the certificate relevant to this discussion include the following: Cause of Death (Part I), Other Significant Conditions Contributing to Death (Part II), Manner of Death, and, for unnatural deaths, the section labeled “Describe How Injury Occurred.” Recommendations for certifying deaths for several common vignettes in which epilepsy or a seizure-related event is thought to have contributed are provided in Table 3.

4.7.1 | Cause of death

In sudden death among people with epilepsy for which no other cause of death is found, the sudden nature of death and its relationship to epilepsy should be emphasized on the death certificate. In such circumstances, there is no correct terminology that satisfies all. We suggest the following can be used interchangeably as the cause of death: “sudden death due to epilepsy,” “epilepsy,” or “sudden unexpected death in epilepsy.” When an individual with seizures that are not due to epilepsy dies under similar circumstances, listing “seizure disorder” as the cause of death is recommended. Acknowledging that clinical inconsistencies exist in the use of the terms epilepsy and seizure disorder, and that forensic case history terminology is variable, the medical examiner might substitute “seizure disorder” when a clinical diagnosis of epilepsy is not provided. In cases of sudden death due to epilepsy or seizure disorder in which the underlying etiology is known, the underlying etiology should be indicated (eg, epilepsy due to blunt head trauma or seizure disorder due to chronic alcoholism). In cases of death due to status epilepticus, epilepsy should also be mentioned if it is the underlying cause.

4.7.2 | Other significant conditions

Part II of the death certificate should list factors contributing to death that did not result in the underlying cause of death indicated in Part I. Because the mechanism of death in epilepsy- or seizure-related deaths is considered a neurological event fatally disrupting cardiopulmonary function, coexisting cardiovascular or pulmonary disease (eg, moderate coronary artery disease or emphysema) could be interpreted as contributing factors. In decedents with a history
of epilepsy or seizure disorder in which there is witnessed seizure activity at the time of death (or suggestive post-mortem evidence) and cardiac or pulmonary pathology is considered insufficient to be a competing cause, deaths could still be certified as epilepsy, or one of the variations listed above, in Part I with the cardiac and/or pulmonary findings listed as contributing factors in Part II.

In more frequent scenarios involving unwitnessed deaths with a clear competing cause of death (eg, severe coronary artery atherosclerosis), it is recommended that both possible causes of death be indicated on the death certificate. An example would be an individual with epilepsy found dead in bed with 90% atherosclerotic narrowing of the left anterior descending coronary artery. One way to certify this death would be to put “atherosclerotic coronary artery disease” in Part I and “epilepsy” in Part II of the death certificate. Similarly, in an individual with epilepsy who is also found to have alcohol intoxication, both factors should be listed on the death certificate. In such a circumstance, the placement of each diagnosis in either Part I or Part II will depend on the alcohol concentration.

### 4.7.3 Manner of death

A determination of seizure-related death does not preclude a nonnatural manner of death. When drowning cannot be excluded (eg, a decedent with epilepsy found dead, submerged in a bathtub), traditional practice is to attribute death to drowning and the manner as accident. However, addition of “epilepsy” or “seizure disorder” in Part II is encouraged when appropriate, since drowning of a PWE in a bathtub without drug intoxication would be extremely rare, making a seizure-related death likely. It is possible that deaths associated with epilepsy caused by prior injuries can be the result of an accident, homicide, or even suicide, and should be certified as such.\(^71\)

### 4.7.4 How injury occurred

As this death certificate section will pertain to nonnatural deaths only, details regarding how an injury occurred should follow standard practices that often indicate the means and circumstances that led to the injury.

### 5 SUMMARY

The recommendations of this panel are based on the best evidence provided in the medical literature for the investigation, evaluation, and certification of epilepsy-related deaths at the time of review. The likely significant underreporting of such deaths by medical examiners and
coroners hampers advancements in research and public health, but more importantly fails to meet the responsibility of a medicolegal death investigation to provide accurate death certification. Use of these recommendations will improve the detection and reporting of epilepsy-related deaths.

The opinions and conclusions of this paper have been reviewed and approved by the NAME Board of Directors and as such are endorsed by the National Association of Medical Examiners. These opinions and positions are based on a consensus of the current literature, knowledge, and prevailing theories on this topic. As scientific knowledge and experience grow and change, the National Association of Medical Examiners reserves the right to revise or update these opinions.

The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

ACKNOWLEDGMENTS

The authors wish to express their appreciation for travel cost funding provided by the American Epilepsy Society and for the valuable input provided by Margaret Warner from the National Center for Health Statistics, Division of Vital Statistics, Mortality Statistics Branch.

DISCLOSURE OF CONFLICT OF INTEREST

Orrin Devinsky has received funding from the National Institute of Neurologic Disorders and Stroke for SUDEP Research and serves as the Principal Investigator of the North American SUDEP Registry and Sudden Unexplained Death in Childhood Registry and Research Collaborative. He has received research grants from GW Pharmaceuticals, Zogenix, Novartis, and PTC Therapeutics. He is on the Scientific Advisory Board of Tilray, Empatica, Tevard, and EggRock. Daniel Friedman has served as a consultant to LivaNova on SUDEP-related research. He also serves on the executive committee of the North American SUDEP Registry and on the advisory board of the Epilepsy Foundation’s SUDEP Institute. Dale Hesdorffer receives research funding from the National Institute of Neurological Disorders and Stroke/National Institutes of Health, Epilepsy Study Consortium, and Human Epilepsy Project. David Thurman receives funding from UCB, Inc. Torbjörn Tomson has received speaker’s honoraria to his institution from Eisai, LivaNova, UCB, and Sandoz; honoraria to his institution for advisory boards from UCB and Eisai; and research support from GlaxoSmithKline, UCB, Eisai, Bial, Novartis, Stockholm County Council, and Citizens United for Research in Epilepsy. Zian Tseng receives funding for research from the National Heart, Lung, and Blood Institute/National Institutes of Health and the Centers for Disease Control and Prevention. All other authors report no potential conflicts of interest relevant to this article. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

The opinions and conclusions of this paper have been reviewed and approved by the NAME Board of Directors and as such are endorsed by the National Association of Medical Examiners. These opinions and positions are based on a consensus of the current literature, knowledge, and prevailing theories on this topic. As scientific knowledge and experience grow and change, the National Association of Medical Examiners reserves the right to revise or update these opinions. The process by which NAME position papers are initiated, written, reviewed, and approved is publicly available on the NAME website (www.thename.org). All scientific position papers endorsed by the National Association of Medical Examiners automatically expire five years after publication unless reaffirmed, revised, or retired at or before that time. This work is a product of NAME and as such, was not subjected to Academic Forensic Pathology editorial review. The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

ORCID

Daniel Friedman http://orcid.org/0000-0003-1068-1797
Dale Hesdorffer http://orcid.org/0000-0003-1783-5381

REFERENCES


How to cite this article: Middleton O, Atherton D, Bundock E, et al. National Association of Medical Examiners position paper: Recommendations for the investigation and certification of deaths in people with epilepsy. Epilepsia. 2018;00:1–14. https://doi.org/10.1111/epi.14030

APPENDIX

LITERATURE SEARCH STRATEGY

Databases: Medline, Medline In-Process & Other Non-Indexed Citations*, Embase

* Medline In-Process & Other Non-Indexed Citations not limited to humans

1. exp mortality/
2. exp epilepsy/
3. 1 and 2
4. epileps*.ti,ab.
5. seizure?.ti,ab.
6. 4 or 5
7. death?.ti,ab.
8. mortality.mp. or exp Mortality/
9. 7 or 8
10. 6 and 9
11. SUDEP.ti,ab.
12. exp Epilepsy/mo [Mortality]
14. exp Death, Sudden/
15. 13 or 14
16. 6 and 15
17. 3 or 10 or 11 or 12 or 16
18. exp toxicology/
19. toxicology.ti,ab.
20. exp histology/
21. histology.ti,ab.
22. exp Autopsy/
23. exp “Cause of Death”/
24. exp “Coroners and Medical Examiners”/
25. exp Jurisprudence/
26. exp Forensic Medicine/
27. Autopsy.ti,ab.
28. forensic pathology.ti,ab.
29. Autopsies.ti,ab.
30. Autopsied.ti,ab.
31. Postmortem.ti,ab.
32. “Post mortem”.ti,ab.
33. “cause of death”.ti,ab.
34. Coroner?.ti,ab.
35. ((Medical or Forensic) adj Examiner?).ti,ab.
36. Jurisdiction.ti,ab.
37. Jurisprudence.ti,ab.
38. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37
39. (scene adj3 (findings or investigation or examination or death)).ti,ab.
40. (death adj3 (classification or classify or investigate or investigation or certify or certification or determine or determination or cause)).ti,ab.
41. 38 or 39 or 40
42. 17 and 41
43. limit 42 to (English language and humans and yr="1970 -Current")

Database: PubMed.gov (excludes MEDLINE)


Legend: [mesh]=medical subject heading, [tiab]=term appears within title or abstract

AFPJournal

Keywords: Epilepsy OR epileptic OR epilepsy OR seizure OR seizures

Years: 2011–2015
# Field Investigator Epilepsy Death Form

<table>
<thead>
<tr>
<th>ME case number</th>
<th>Name of deceased</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigator</td>
<td>Date (mm/dd/yyyy) Time (24-hour clock)</td>
</tr>
</tbody>
</table>

## Witness/Family Information

- Obtained information from
- Relationship to deceased:

## Hospital or clinic where treated?
- Did the deceased have epilepsy or a seizure disorder? [ ] Yes [ ] No [ ] Unknown
- When was the victim last seen alive and well? Date: [ ] Time (24 hr) [ ] OR [ ] Unknown
- Was the last observed seizure on the date of death? [ ] Yes [ ] No [ ] Unknown
- Were medications found at scene? [ ] Yes [ ] No [ ] Unknown

### Last drugs and number of pills in bottle

<table>
<thead>
<tr>
<th>Drug</th>
<th>#bottles</th>
<th>#pills</th>
</tr>
</thead>
</table>

## Seizure description

Instructions: described the usual seizure(s) as narrative; what happens first, then what happens & how does it end

## Where did seizures usually occur: Circle all that apply

- Morning
- Afternoon
- Evening
- During sleep
- Shortly after awakening

## Did the deceased: Circle all that apply

- Drink heavily?
- Use marijuana?
- Use other illicit drugs?
- Take insulin?
- Use cocaine?
- Have meningitis or encephalitis?
- Have prior head injury?
- Use heroin?
- Have antidepressant drugs?
- Have depression?
- Have brain surgery?
- Have chronic health problems? [ ] Yes [ ] No [ ] Unknown

## Which anticonvulsant medication(s) was the patient currently taking? Circle all that apply

- No antiseizure drugs
- Carbamazepine (Tegretol, Tegretol XR, Carbatrol)
- Clobazam (Onfi, Brizin)
- Clonazepam (Klonopin)
- Clonazepam (Trancen)
- Divalproex Sodium (Depakene, Depakote, Depakote ER)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)
- Ethosuximide (Zarontin)